Is Shukra Pharmaceuticals Ltd (524632) a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Shukra Pharmaceuticals Ltd is a below average quality company .

Is Shukra Pharmaceuticals Ltd (524632) undervalued or overvalued?

The key valuation ratios of Shukra Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Shukra Pharmaceuticals Ltd (524632) share price return in the past 10 years?

Shukra Pharmaceuticals Ltd share price has appreciated 59.4% annually (CAGR) over the past ten years.

Is Shukra Pharmaceuticals Ltd (524632) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Shukra Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Shukra Pharmaceuticals Ltd (524632)?

Company share prices are keep on changing according to the market conditions. The current trading price of Shukra Pharmaceuticals Ltd (524632) on 17-Apr-2026 16:59:59 at 16:59 is 36.06.

What is the P/E ratio of Shukra Pharmaceuticals?

The latest standalone P/E ratio of Shukra Pharmaceuticals as of 17-Apr-2026 is 54.15.

What is the P/B ratio of Shukra Pharmaceuticals Ltd (524632)?

The latest standalone P/B ratio of Shukra Pharmaceuticals Ltd (524632) as of 17-Apr-2026 is 18.32.

What is the 52-week high and low of Shukra Pharmaceuticals Ltd (524632)?

The 52-week high of Shukra Pharmaceuticals Ltd (524632) is Rs. 65.26 and the 52-week low is Rs. 11.74.

Shukra Pharmaceuticals Ltd (524632) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Shukra Pharmaceuticals Ltd (524632)
Brand: Shukra Pharmaceuticals

Shukra Pharmaceuticals Ltd (524632) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Shukra Pharmaceuticals Ltd (524632)

BSE: 524632 NSE:

Key Metrics

Market Cap

₹1,579 Cr.

P/E Ratio

54.15

Price to Book (P/B)

18.32

Price to Sales (P/S)

24.80

EV/EBITDA

38.79

Return on Capital Employed (ROCE)

21.80%

Current Price

₹36.1

Return on Equity (ROE)

15.90%

Return on Assets (ROA)

11.63%

Operating Profit Margin

39.1%

Net Profit Margin

29.38%

Gross Profit Margin

50.2%

Book Value per Share

₹2

Sales Growth (YoY)

-56.3%

Sales Growth (3 Years)

16.73%

Operating Profit Growth (1 Year)

-34.38%

Operating Profit Growth (3 Years)

63.92%

Net Profit Growth (1 Year)

-48.33%

52-Week Low / High

₹12 / 65

Net Profit Growth (3 Years)

133.65%

Dividend Yield

0.05%

Promoter Holding

50.96%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Shukra Pharmaceuticals Ltd?

Shukra Pharmaceuticals Ltd revenue growth is -56.3% for FY-2025 , which is below its 5 year CAGR of 22.4% , indicating slower growth.

Q.1 Promoter shareholding and pledge status of Shukra Pharmaceuticals Ltd?

Promoters hold 50.96% of the Shukra Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Shukra Pharmaceuticals Ltd vs industry peers?

Shukra Pharmaceuticals Ltd revenue CAGR is 22.43% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.

Q.1 Which industry/sub-sector does Shukra Pharmaceuticals Ltd belong to?

Shukra Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Stock return of Shukra Pharmaceuticals Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 59.4% based on the current price.

DeciZen - make an informed investing decision on Shukra Pharma

Based on:

Data

Overall Rating ⓘ
Login to view analysis.

1. Quality

2. Valuation ⓘ

3. Price Trend

Shukra Pharmaceuticals stock performance

Key Ratios

Is Shukra Pharmaceuticals Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	2.4%	7.4%	5.9%	3.6%	0.8%	0.5%	5.8%	18.9%	44.2%	21.8%	-
Value Creation Index ⓘ	-0.8	-0.5	-0.6	-0.7	-1.0	-1.0	-0.6	0.4	2.2	0.6	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	4.8	5.1	5.3	5.7	11.9	11.2	20.5	58.8	74.6	32.6	64
Sales YoY Gr.	-	6.4%	3.9%	6%	109.4%	-5.5%	83%	187.1%	26.8%	-56.3%	-
Adj EPS ⓘ	0	0	0	0	-0	0	0	0.1	0.4	0.2	0.7
YoY Gr.	-	0%	0%	0%	-100%	NA	NA	400%	320%	-47.6%	-
BVPS (₹) ⓘ	0.5	0.5	0.5	0.5	0.5	0.5	0.5	1.6	1.3	1.4	2
Adj Net Profit ⓘ	0.5	0.5	0.5	0.5	-0	0.1	0.8	4.4	18.5	9.6	29
Cash Flow from Ops. ⓘ	2.7	-0.3	0.8	0.3	1.2	0.5	8	3.2	-5.2	7.9	-
Debt/CF from Ops. ⓘ	0	-0.1	4.3	23.4	6.5	18.2	0.4	1.6	-0.6	0.5	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	23.6%	22.4%	16.7%	-56.3%
Adj EPS ⓘ	30.5%	NA	122.4%	-47.6%
BVPSⓘ	13.3%	23.1%	38.7%	9.1%
Share Price	59.4%	148.6%	176.3%	84.9%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	3.6	3.5	3.6	3	-0.2	0.9	4.7	21.2	44.7	15.9	39.3
Op. Profit Mgn % ⓘ	24.5	28.5	30.2	29.1	13	12.9	14.1	9.1	26	39.1	55.5
Net Profit Mgn % ⓘ	10.4	9.8	9.9	8.2	-0.3	1.2	3.7	7.5	24.9	29.4	46.1
Debt to Equity ⓘ	0	0	0.2	0.4	0.5	0.6	0.2	0.2	0.1	0.1	-
Working Cap Days ⓘ	392	379	467	526	334	487	277	201	233	558	365
Cash Conv. Cycle ⓘ	75	64	31	40	39	132	54	-9	10	111	269

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	0.7	-
TTM Sales (₹ Cr.)	63.7	-
BVPS (₹) ⓘ	2	-
Reserves (₹ Cr.) ⓘ	42	-
P/BV ⓘ	18.32	-
PE ⓘ	54.15	-

From the Market
52 Week Low / High (₹)	11.74 / 65.26
All Time Low / High (₹)	0.00 / 65.26
Market Cap (₹ Cr.)	1,579
Equity (₹ Cr.)	43.8
Face Value (₹)	1
Industry PE ⓘ	42.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Shukra Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	5	5	5	6	12	11	20	59	75	33
Operating Expenses ⓘ +	4	4	4	4	10	10	18	53	55	20
Manufacturing Costs	0	0	0	0	2	2	0	0	0	1
Material Costs	2	1	1	1	3	3	10	45	44	8
Employee Cost	1	1	1	2	4	4	5	4	5	5
Other Costs ⓘ	1	1	1	1	1	1	3	4	6	6
Operating Profit ⓘ	1	1	2	2	2	1	3	5	19	13
Operating Profit Margin (%)	24.5%	28.5%	30.2%	29.1%	13.0%	12.9%	14.1%	9.1%	26.0%	39.1%
Other Income ⓘ +	0	0	0	0	0	0	0	1	3	4
Exceptional Items ⓘ	-1	0	-0	0	0	-0	0	0	0	0
Interest ⓘ	0	0	0	0	0	0	0	0	0	1
Depreciation ⓘ	0	0	1	1	1	1	2	2	2	3
Profit Before Tax ⓘ	0	1	1	1	0	0	1	4	20	13
Tax ⓘ	0	1	0	0	0	-0	0	0	1	4
Profit After Tax	0	1	1	0	0	0	1	4	19	10
PAT Margin (%)	2.5%	9.8%	9.8%	8.2%	0.3%	1.7%	3.7%	7.5%	24.9%	29.4%
Adjusted EPS (₹)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	0.2
Dividend Payout Ratio (%)	0%	16%	15%	17%	0%	0%	10%	4%	6%	5%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	14	15	15	15	15	16	16	25	58	63
Share Capital ⓘ	2	2	2	2	2	2	2	4	11	44
Reserves ⓘ	13	13	13	14	14	14	15	21	47	19
Debt +	0	0	4	6	8	10	3	4	3	3
Long Term Debt	0	0	4	6	8	10	3	4	3	3
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	1	1	2	3	6	5	9	34	7	9
Others Liabilities ⓘ	3	3	4	4	4	5	7	12	10	12
Total Liabilities ⓘ	17	19	24	28	34	36	35	75	78	87
Fixed Assets
Net Fixed Assets ⓘ +	10	10	14	16	17	18	18	20	20	19
Gross Block	20	21	26	29	32	34	35	40	41	43
Accumulated Depreciation	11	11	12	13	14	16	18	19	21	24
CWIP ⓘ	2	2	2	2	2	2	2	2	2	2
Investments ⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	0	0	0	0	1	2	4	3	2	10
Trade Receivables	1	2	3	5	8	10	7	30	25	9
Cash Equivalents	2	1	0	0	0	1	0	4	10	12
Others Assets ⓘ	3	4	5	5	5	4	4	16	19	35
Total Assets ⓘ	17	19	24	28	34	36	35	75	78	87

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	3	-0	1	0	1	1	8	3	-5	8
PBT ⓘ	0	1	1	1	0	0	1	4	20	13
Adjustment ⓘ	0	0	1	1	2	1	2	2	2	2
Changes in Working Capital ⓘ	2	-1	-1	-1	-1	-1	5	-3	-26	-4
Tax Paid ⓘ	-0	-0	-0	-0	0	0	-0	-0	-1	-4
Cash Flow From Investing Activity ⓘ +	-0	-1	-5	-2	-3	-2	-2	-4	-1	-1
Capex	-0	-1	-5	-2	-3	-2	-2	-4	-2	-3
Net Investments	-0	-0	-0	-0	-0	-0	-0	0	0	0
Others ⓘ	0	0	-0	-0	0	0	0	0	1	1
Cash Flow From Financing Activity ⓘ +	-1	0	3	2	2	2	-7	5	12	-5
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	5	14	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	2	-6	1	-1	0
Interest Paid ⓘ	0	0	0	0	0	0	-0	-0	-0	-1
Dividend Paid ⓘ	0	0	-0	-0	0	0	0	-0	-0	-4
Others ⓘ	-1	0	4	2	2	0	0	-0	-0	0
Net Cash Flow ⓘ	1	-1	-0	0	-0	0	-0	4	6	2

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	0.85	3.51	3.55	3.04	0.23	1.21	4.7	21.16	44.7	15.9
ROCE (%)	2.4	7.41	5.94	3.62	0.77	0.54	5.79	18.85	44.24	21.8
Asset Turnover Ratio	0.27	0.28	0.27	0.25	0.44	0.32	0.58	1.07	0.98	0.4
PAT to CFO Conversion(x)	N/A	-0	1	N/A	N/A	N/A	8	0.75	-0.26	0.8
Working Capital Days
Receivable Days	55	121	171	228	177	289	153	117	134	186
Inventory Days	67	27	15	11	22	50	50	22	13	69
Payable Days	97	245	526	872	563	762	246	170	168	370

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Shukra Pharmaceuticals Ltd FAQs

The current trading price of Shukra Pharma on 17-Apr-2026 16:59 is ₹36.06.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Shukra Pharma stood at ₹1,579 Cr

The latest P/E ratio of Shukra Pharma as of 16-Apr-2026 is 54.15.

The latest P/B ratio of Shukra Pharma as of 16-Apr-2026 is 18.32.

The 52-week high of Shukra Pharma is ₹65.26 and the 52-week low is ₹11.74.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Shukra Pharma is ₹63.67 ( Cr.) .

About Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals is an ambitious organisation with a deep rooted focus on sustainability with its impressive range of solutions. The company is committed to deliver excellence across National & Global markets. It is a public limited organisation with globally acclaimed manufacturing facilities.

The company is strongly committed to its values that guide it - The Shukra Group in serving the needs of its stakeholders including customers, suppliers, employees and other interest groups by large. Shukra stands for uncompromising quality and efficiency to deliver proven solutions delivered by passionate and motivated team of individuals.

The company boasts fully integrated structure for manufacturing general formulations like Tablet, Capsules and small volume parenteral since 2017. Along with internationally accredited facilities it invests in people.

The company has embarked upon its ambitious journey in the field of Pharamaceutical (date of inception) with a fully integrated plant in Rakanpor in Kalol, Gandhinagar - Gujarat. Since then, there was no looking back, within a short span of (years) the company has come a long way in making its mark in the sector.

The company has now developed an internationally accredited Laboratory in Ahmedabad where each product and solutions are developed under stringent quality processes.

Business area of the company

The company is engaged in the business of manufacturing and trading of pharmaceuticals Products, laboratory testing.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Shukra Pharmaceuticals Ltd (524632) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Shukra Pharma Share Price